PAVmed Q2 GAAP net loss $10.9M; Lucid EsoGuard test volume record 3,147 (up 31% QoQ)

PAVmed Inc.

2024-Q2 EPS reported -$3.78 revenue$2,000,000

Q2 revenue $1.0M from EsoGuard test; GAAP net loss attributable to common $10.9M ($1.19/sh).
Adjusted non-GAAP loss $7.7M ($0.84/sh). Cash and equivalents $25.5M at June 30, 2024.
Lucid commercial EsoGuard tests: 3,147 in Q2 (single-quarter record), +31% sequential, +44% YoY.
Lucid held productive meeting with CMS MAC Palmetto GBA's MolDX program for EsoGuard coverage.
Veris launched pilot with Ohio State's James Cancer Hospital; actively pursuing independent financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.